JP2022506898A - Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物 - Google Patents
Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物 Download PDFInfo
- Publication number
- JP2022506898A JP2022506898A JP2021525010A JP2021525010A JP2022506898A JP 2022506898 A JP2022506898 A JP 2022506898A JP 2021525010 A JP2021525010 A JP 2021525010A JP 2021525010 A JP2021525010 A JP 2021525010A JP 2022506898 A JP2022506898 A JP 2022506898A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- compound according
- ring
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *CN(*)CCC(CCCCC1)C1N=C Chemical compound *CN(*)CCC(CCCCC1)C1N=C 0.000 description 104
- KFRVHXBESLWOOJ-UHFFFAOYSA-N Cc1c(CCC2)c2cc2c1CCC2 Chemical compound Cc1c(CCC2)c2cc2c1CCC2 KFRVHXBESLWOOJ-UHFFFAOYSA-N 0.000 description 2
- WDJQZSZWEDCJNI-UHFFFAOYSA-N N=S(c1c2ccc(Br)c1)(NC2=O)=O Chemical compound N=S(c1c2ccc(Br)c1)(NC2=O)=O WDJQZSZWEDCJNI-UHFFFAOYSA-N 0.000 description 2
- USYLXYRMFWLCPW-UHFFFAOYSA-N CC(C)(CS(N)(=N1)=O)C1=O Chemical compound CC(C)(CS(N)(=N1)=O)C1=O USYLXYRMFWLCPW-UHFFFAOYSA-N 0.000 description 1
- GGIUWHPIGAMXBB-UHFFFAOYSA-N CC(C)(CS(N)(=O)=O)C(O)OC Chemical compound CC(C)(CS(N)(=O)=O)C(O)OC GGIUWHPIGAMXBB-UHFFFAOYSA-N 0.000 description 1
- CUFBRERBLPVHBA-UHFFFAOYSA-N CC(C)(c1cccc(C(CC(N2)=O)S2(=N)=O)c1)O Chemical compound CC(C)(c1cccc(C(CC(N2)=O)S2(=N)=O)c1)O CUFBRERBLPVHBA-UHFFFAOYSA-N 0.000 description 1
- FTDZLZLELGEEHQ-UHFFFAOYSA-N CC(C1(COC1)C1)(NS1(O)=[IH])O Chemical compound CC(C1(COC1)C1)(NS1(O)=[IH])O FTDZLZLELGEEHQ-UHFFFAOYSA-N 0.000 description 1
- CDVNPAFBHKCLDJ-VOTSOKGWSA-N CC/C(/C)=C(\C)/N=C=O Chemical compound CC/C(/C)=C(\C)/N=C=O CDVNPAFBHKCLDJ-VOTSOKGWSA-N 0.000 description 1
- JGXTZWBGFQWFIZ-BQYQJAHWSA-N CC/C(/C)=C(\CC)/C#N Chemical compound CC/C(/C)=C(\CC)/C#N JGXTZWBGFQWFIZ-BQYQJAHWSA-N 0.000 description 1
- RCQNTUCZVOELLF-QXMHVHEDSA-N CC1(C(/C(/C2CC2)=C(/C2CC2)\N)N)[F]CCC1 Chemical compound CC1(C(/C(/C2CC2)=C(/C2CC2)\N)N)[F]CCC1 RCQNTUCZVOELLF-QXMHVHEDSA-N 0.000 description 1
- XTSCMWCPSJKRTQ-UHFFFAOYSA-N CC1C(C)C(C2)C2C1 Chemical compound CC1C(C)C(C2)C2C1 XTSCMWCPSJKRTQ-UHFFFAOYSA-N 0.000 description 1
- VUSNISWLMAHVEY-UHFFFAOYSA-N CN(CC1(COC1)C1)S1(=NC(Nc1c(CCC2)c2cc2c1CCC2)=O)=O Chemical compound CN(CC1(COC1)C1)S1(=NC(Nc1c(CCC2)c2cc2c1CCC2)=O)=O VUSNISWLMAHVEY-UHFFFAOYSA-N 0.000 description 1
- XTUVJUMINZSXGF-UHFFFAOYSA-N CNC1CCCCC1 Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 1
- RURYWBBDYLSGQT-UHFFFAOYSA-N CNCC(CC1)=CC(S(N2C=C)(=NC(N(C=C)c3c(CCC4)c4cc4c3CCC4)=C)=S)=C1C2=C Chemical compound CNCC(CC1)=CC(S(N2C=C)(=NC(N(C=C)c3c(CCC4)c4cc4c3CCC4)=C)=S)=C1C2=C RURYWBBDYLSGQT-UHFFFAOYSA-N 0.000 description 1
- SBGNRRJNMWFDTP-UHFFFAOYSA-N COC(C1(CS(N)(=O)=O)COC1)=O Chemical compound COC(C1(CS(N)(=O)=O)COC1)=O SBGNRRJNMWFDTP-UHFFFAOYSA-N 0.000 description 1
- JWTKVHMWVABDPH-UHFFFAOYSA-N COC(Cc(cc1S(N2)(=N)=O)ccc1C2=O)=O Chemical compound COC(Cc(cc1S(N2)(=N)=O)ccc1C2=O)=O JWTKVHMWVABDPH-UHFFFAOYSA-N 0.000 description 1
- SJHQHXVULCVKKM-UHFFFAOYSA-N COC(c(c(SCl)c1)ccc1Cl)=O Chemical compound COC(c(c(SCl)c1)ccc1Cl)=O SJHQHXVULCVKKM-UHFFFAOYSA-N 0.000 description 1
- XQDVPWISGLMASM-UHFFFAOYSA-N COC(c(cc1)cc(S(N2)(=NC(Nc3c(CCC4)c4cc4c3CCC4)=O)=O)c1C2=O)=O Chemical compound COC(c(cc1)cc(S(N2)(=NC(Nc3c(CCC4)c4cc4c3CCC4)=O)=O)c1C2=O)=O XQDVPWISGLMASM-UHFFFAOYSA-N 0.000 description 1
- YLXAMHXQOPJCRX-UHFFFAOYSA-N COC(c(ccc(Cl)c1)c1S(N)(=O)=O)=O Chemical compound COC(c(ccc(Cl)c1)c1S(N)(=O)=O)=O YLXAMHXQOPJCRX-UHFFFAOYSA-N 0.000 description 1
- OLHOOEUFJBQGJV-OAQYLSRUSA-N CO[C@H](C#[P](c1ccccc1)(c1ccccc1)c1ccccc1)O Chemical compound CO[C@H](C#[P](c1ccccc1)(c1ccccc1)c1ccccc1)O OLHOOEUFJBQGJV-OAQYLSRUSA-N 0.000 description 1
- OOUCVEDOYREYCF-UHFFFAOYSA-N CS(N)(=NC(Nc1c(CCC2)c2cc2c1CCC2)=O)=O Chemical compound CS(N)(=NC(Nc1c(CCC2)c2cc2c1CCC2)=O)=O OOUCVEDOYREYCF-UHFFFAOYSA-N 0.000 description 1
- DBPYBCVDOATROT-SSDOTTSWSA-N C[C@H]1c2nc(CCC3)c3c(N)c2CC1 Chemical compound C[C@H]1c2nc(CCC3)c3c(N)c2CC1 DBPYBCVDOATROT-SSDOTTSWSA-N 0.000 description 1
- ZLASOJASASFHKP-UHFFFAOYSA-N N=S(C(Cc1ccccc1)C1)(NC1=O)=O Chemical compound N=S(C(Cc1ccccc1)C1)(NC1=O)=O ZLASOJASASFHKP-UHFFFAOYSA-N 0.000 description 1
- ANCUKHQRHSKDPQ-UHFFFAOYSA-N N=S(CCC1Cc2ccccc2)(NC1=O)=O Chemical compound N=S(CCC1Cc2ccccc2)(NC1=O)=O ANCUKHQRHSKDPQ-UHFFFAOYSA-N 0.000 description 1
- VCTXRPUMMWULJC-UHFFFAOYSA-N N=S(c1c2ccc(-[n]3nccc3)c1)(NC2=O)=O Chemical compound N=S(c1c2ccc(-[n]3nccc3)c1)(NC2=O)=O VCTXRPUMMWULJC-UHFFFAOYSA-N 0.000 description 1
- SYLFIXMHCIHNEO-UHFFFAOYSA-N N=S(c1c2ccc(Cl)c1)(NC2=O)=[IH] Chemical compound N=S(c1c2ccc(Cl)c1)(NC2=O)=[IH] SYLFIXMHCIHNEO-UHFFFAOYSA-N 0.000 description 1
- VNIOOUOAAXONNK-UHFFFAOYSA-N NC(C1(CS(I)(=O)=[IH])COC1)=O Chemical compound NC(C1(CS(I)(=O)=[IH])COC1)=O VNIOOUOAAXONNK-UHFFFAOYSA-N 0.000 description 1
- RFWIPNVBCDWNMS-UHFFFAOYSA-N NC1OC1c1ccc(CO)cc1S(NC(Nc1c(CCC2)c2cc2c1CCC2)=O)(I)=O Chemical compound NC1OC1c1ccc(CO)cc1S(NC(Nc1c(CCC2)c2cc2c1CCC2)=O)(I)=O RFWIPNVBCDWNMS-UHFFFAOYSA-N 0.000 description 1
- YVRXURLYBCMBFX-UHFFFAOYSA-N NS(CC1(COC1)C(O)O)(=O)=O Chemical compound NS(CC1(COC1)C(O)O)(=O)=O YVRXURLYBCMBFX-UHFFFAOYSA-N 0.000 description 1
- PAOSNHFPSMMFKD-UHFFFAOYSA-N Nc1c(CCC2)c2nc(C2CC2)c1 Chemical compound Nc1c(CCC2)c2nc(C2CC2)c1 PAOSNHFPSMMFKD-UHFFFAOYSA-N 0.000 description 1
- PZHZZPJVIFYGOC-UHFFFAOYSA-N O=C(CC1)NS1(=NC(CCCc1c(CCC2)c2cc2c1CCC2)=[U])=O Chemical compound O=C(CC1)NS1(=NC(CCCc1c(CCC2)c2cc2c1CCC2)=[U])=O PZHZZPJVIFYGOC-UHFFFAOYSA-N 0.000 description 1
- UYBZBDIWTYRSAW-UHFFFAOYSA-N O=C=Nc1c(CCC2)c2cc2c1CCC2 Chemical compound O=C=Nc1c(CCC2)c2cc2c1CCC2 UYBZBDIWTYRSAW-UHFFFAOYSA-N 0.000 description 1
- ZGYCWYOXGLUDLF-UHFFFAOYSA-N O=CNc1c(CCC2)c2cc2c1CCC2 Chemical compound O=CNc1c(CCC2)c2cc2c1CCC2 ZGYCWYOXGLUDLF-UHFFFAOYSA-N 0.000 description 1
- BECCXGVWQNVLEH-UHFFFAOYSA-N OCc(cc1S(N2)(=NC(Nc3c(CCC4)c4cc4c3CCC4)=O)=O)ccc1C2=O Chemical compound OCc(cc1S(N2)(=NC(Nc3c(CCC4)c4cc4c3CCC4)=O)=O)ccc1C2=O BECCXGVWQNVLEH-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760244P | 2018-11-13 | 2018-11-13 | |
| US201862760248P | 2018-11-13 | 2018-11-13 | |
| US201862760279P | 2018-11-13 | 2018-11-13 | |
| US62/760,248 | 2018-11-13 | ||
| US62/760,279 | 2018-11-13 | ||
| US62/760,244 | 2018-11-13 | ||
| US201962795373P | 2019-01-22 | 2019-01-22 | |
| US62/795,373 | 2019-01-22 | ||
| US201962796361P | 2019-01-24 | 2019-01-24 | |
| US201962796356P | 2019-01-24 | 2019-01-24 | |
| US62/796,361 | 2019-01-24 | ||
| US62/796,356 | 2019-01-24 | ||
| PCT/US2019/060775 WO2020102100A1 (en) | 2018-11-13 | 2019-11-11 | Compounds and compositions for treating conditions associated with nlrp activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506898A true JP2022506898A (ja) | 2022-01-17 |
| JPWO2020102100A5 JPWO2020102100A5 (https=) | 2022-11-21 |
| JP2022506898A5 JP2022506898A5 (https=) | 2022-11-21 |
Family
ID=68916531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525010A Pending JP2022506898A (ja) | 2018-11-13 | 2019-11-11 | Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12134611B2 (https=) |
| EP (1) | EP3880666B1 (https=) |
| JP (1) | JP2022506898A (https=) |
| CN (1) | CN113166081A (https=) |
| ES (1) | ES2957692T3 (https=) |
| WO (1) | WO2020102100A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3649112A1 (en) * | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| CA3105521A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| EP3986879B1 (en) * | 2019-06-21 | 2024-10-02 | AC Immune SA | Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| CN117185965B (zh) * | 2023-09-18 | 2024-10-11 | 安徽金桐精细化学有限公司 | 一种磺酸基丙烯酸盐复配表面活性剂的制备方法 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2026064385A1 (en) * | 2024-09-18 | 2026-03-26 | Ventus Therapeutics U.S., Inc. | Oxadiazolone inhibitors of nlrp3 and uses thereof |
| CN119775202A (zh) * | 2024-12-31 | 2025-04-08 | 河南旭瑞新材料科技有限公司 | 一种2-巯基烟酰甘氨酸的合成方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018510207A (ja) * | 2015-02-16 | 2018-04-12 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| AU630497B2 (en) | 1989-09-05 | 1992-10-29 | Immunex Corporation | Tumor necrosis factor-alpha and -beta receptors |
| ZA929699B (en) | 1991-12-20 | 1994-06-14 | Lilly Co Eli | Sulfonimidamides |
| US5705398A (en) | 1994-03-02 | 1998-01-06 | The Scripps Research Institute | Methods for identifying inhibitors of LPS-mediated LBP binding |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| DK0929578T3 (da) | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| CA2329065A1 (en) | 1998-05-05 | 1999-11-11 | Francisco Xavier Talamas | Pyrazole derivatives as p-38 map kinase inhibitors |
| KR101120857B1 (ko) | 2003-06-26 | 2012-04-12 | 노파르티스 아게 | 5원의 헤테로사이클-기재 ｐ38 키나제 억제제 |
| US20080280910A1 (en) | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| US8884006B2 (en) | 2011-09-19 | 2014-11-11 | University Of Puerto Rico | Small-molecule inhibitors of Rac1 in metastatic breast cancer |
| ITMI20131658A1 (it) | 2013-10-08 | 2015-04-09 | Getters Spa | Combinazione di materiali per dispositivi di rilascio di mercurio e dispositivi contenenti detta combinazione di materiali |
| US9714288B2 (en) | 2014-09-30 | 2017-07-25 | The Regents Of The University Of California | Antisense compounds and uses thereof |
| US11447460B2 (en) * | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| US11339136B2 (en) | 2016-04-18 | 2022-05-24 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| CA3021349A1 (en) | 2016-04-19 | 2017-10-26 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| JP6962941B2 (ja) | 2016-06-14 | 2021-11-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Ａｐｊ受容体アゴニストとしての４−ヒドロキシ−３−スルホニルピリジン−２（１ｈ）−オン |
| EP3571187B1 (en) | 2017-01-23 | 2023-11-22 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| WO2018225018A1 (en) | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
| JP7349981B2 (ja) * | 2017-07-24 | 2023-09-25 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| ES2988798T3 (es) | 2017-07-24 | 2024-11-21 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CA3105521A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| BR112021003665A2 (pt) | 2018-09-13 | 2021-05-18 | Bayer Aktiengesellschaft | derivados de heterocicleno como agentes de controle de pragas |
| EP3911323A4 (en) | 2019-01-18 | 2022-11-16 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| EP3986879B1 (en) | 2019-06-21 | 2024-10-02 | AC Immune SA | Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators |
-
2019
- 2019-11-11 US US17/292,887 patent/US12134611B2/en active Active
- 2019-11-11 CN CN201980078239.1A patent/CN113166081A/zh active Pending
- 2019-11-11 WO PCT/US2019/060775 patent/WO2020102100A1/en not_active Ceased
- 2019-11-11 ES ES19821320T patent/ES2957692T3/es active Active
- 2019-11-11 EP EP19821320.9A patent/EP3880666B1/en active Active
- 2019-11-11 JP JP2021525010A patent/JP2022506898A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018510207A (ja) * | 2015-02-16 | 2018-04-12 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2957692T3 (es) | 2024-01-24 |
| US20230024859A1 (en) | 2023-01-26 |
| EP3880666A1 (en) | 2021-09-22 |
| EP3880666B1 (en) | 2023-06-28 |
| WO2020102100A1 (en) | 2020-05-22 |
| CN113166081A (zh) | 2021-07-23 |
| WO2020102100A9 (en) | 2022-01-06 |
| US12134611B2 (en) | 2024-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7654767B2 (ja) | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 | |
| JP7730759B2 (ja) | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 | |
| JP2022505525A (ja) | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 | |
| JP2021529187A (ja) | Ｎｌｒｐモジュレータ | |
| JP2022506898A (ja) | Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物 | |
| JP2020528889A (ja) | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 | |
| JP2022507506A (ja) | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 | |
| JP2022518260A (ja) | Ｎｌｒｐ活性に関連する状態を治療するためのスルホンイミドアミド化合物及び組成物 | |
| US20220227707A1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| JP2022507505A (ja) | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 | |
| JP2022505562A (ja) | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 | |
| JP2021529186A (ja) | Ｎｌｒｐ調節剤 | |
| JP2022506891A (ja) | Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物 | |
| HK40103462A (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| HK40024570A (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| HK40024570B (en) | Compounds and compositions for treating conditions associated with nlrp activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221111 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221111 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231005 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231024 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240105 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240521 |